Carl Thiem Klinikum gGmbH
- Address
- Thiemstrasse 111, Spremberger Vorstadt, 03048 Cottbus, Germany
Hemic and Lymphatic Diseases
At Carl Thiem Klinikum gGmbH in Cottbus, clinical research in Hemic and Lymphatic Diseases focuses on blood cancers and related disorders in both adults and children. The studies are designed to test new treatment approaches, improve response rates, and better understand survival outcomes in acute myeloid leukemia, high-risk myelodysplastic neoplasia, and other aggressive blood malignancies.
- Testing new treatment combinations for acute myeloid leukemia to improve remission results and support transplant planning
- Evaluating whether venetoclax and azacitidine can offer a better option for patients who are not suited to standard induction therapy
- Studying treatment strategies for mature aggressive B-cell lymphoma and leukemia in children and adolescents
These trials reflect a strong interest in finding more effective and better tolerated therapies for complex hematologic cancers, with attention to both disease control and long-term outcomes.
Neoplasms
Research in Neoplasms at this hospital-based site includes cancers of the blood and solid tumors, with studies spanning pediatric and adult populations. The main goal is to refine treatment effectiveness, strengthen diagnostic assessment, and improve survival for patients with EBV-positive nasopharyngeal carcinoma, breast cancer, and anaplastic large cell lymphoma.
- Assessing whether treatment can raise complete response rates in EBV-positive nasopharyngeal carcinoma and allow gentler radiotherapy
- Exploring new strategies for patients with advanced HER2-negative, hormone receptor positive breast cancer
- Evaluating vinblastine for children and adolescents with standard-risk ALK-positive anaplastic large cell lymphoma
The work combines treatment development with outcome-focused research, aiming to improve cancer care across several difficult-to-treat tumor types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1GPOH gGmbH2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Carl Thiem Klinikum gGmbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL) | Universitaet Leipzig | Phase II | Not Recruiting | May 2023 | Nov 2025 |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 2 | Unknown | 2017-07-12 | 2017-07-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.